|Bid||18.49 x 800|
|Ask||21.22 x 2200|
|Day's Range||18.73 - 19.81|
|52 Week Range||7.76 - 24.24|
|Beta (3Y Monthly)||2.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.50|
CAMBRIDGE, Mass., April 15, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, granted restricted stock units and a non-qualified stock option to Robert Hesslein as inducements material to his entering an employment agreement with Voyager to serve as its general counsel. The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4) and became effective upon the commencement of Mr. Hesslein’s employment on April 1, 2019. Mr. Hesslein received a restricted stock unit award for 28,125 shares of Voyager common stock and a non-qualified stock option to purchase 168,750 shares of Voyager common stock.
CAMBRIDGE, Mass., April 02, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for Parkinson’s disease, in the peer-reviewed journal, Annals of Neurology. The publication titled “Magnetic Resonance Imaging-Guided Phase 1 Trial of Putaminal AADC Gene Therapy for Parkinson's Disease,” can be accessed online.
MRI Interventions, Inc. (MRIC) a platform neurosurgery company developing products designed to deliver navigation, ablation, deep brain stimulation, aspiration, biopsy and gene therapy today announced a collaboration with Voyager Therapeutics, Inc. (VYGR) to design, manufacture and supply the Variable Trajectory Array Guide, or V-TAG, neurosurgical device for Voyager. Under the collaboration, Voyager transferred its existing 510(k) clearance for the V-TAG device to MRI Interventions who will manufacture and supply the device as a choice for neurosurgeons, along with MRI’s Clearpoint® system, for use in Voyager’s RESTORE-1 Phase 2 trial of its VY-AADC gene therapy program for Parkinson’s disease. “We continue to evolve and expand our relationship with Voyager with the common goal of delivering gene therapy to specific regions of the brain with accuracy to give our patients the best possible chance at success,” commented Joe Burnett, President and CEO at MRI Interventions.
HENDERSON, NV / ACCESSWIRE / March 8, 2019 / The past few weeks have been busy with big bio taking over smaller biotechs developing novel therapies. Roche (RHHBY) said it would spend $4.8 billion in a ...
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Emerging revolutionary treatments promise possible cures for diseases like hemophilia and muscular dystrophy—and opportunities for investors
Initiated RESTORE-1 Phase 2 trial for VY-AADC for Parkinson’s disease Began IND-enabling preclinical studies for ALS-SOD1 and Huntington’s disease programs Recently announced.
AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.
CORAL GABLES, FL/ ACCESSWIRE / February 22, 2019 / With the new year only a few months old, the biotech stock market is already whirring with the excitement surrounding companies developing nuanced approaches to creating a wide array of new forms of treatment options for patients in need of care. Naturally, companies in the biotech sector working to address these challenges are garnering significant notoriety among consumers as well as investors. Premier Health Group (PHGRF) (PHGI), Ocular Therapeutix Inc (OCUL), Voyager Therapeutics Inc (VYGR), and Amarin Corporation plc (NASDAQ:AMRN) represent 4 biotech stocks stepping up their game on Friday.
Voyager (Nasdaq: VYGR) is expanding its partnership with pharmaceutical company AbbVie (Nasdaq: ABBV), launching a research effort to develop antibody treatments that can be delivered directly to the brain and target a protein called alpha-synuclein.
surged more than 20% on Friday after the gene therapy company announced a collaboration agreement with pharmaceutical giant AbbVie Inc. Under terms of the agreement, Voyager will receive $65 million upfront and up to $245 million in preclinical and phase 1 option payments, as well as up to an additional $728 million in potential development, regulatory, and commercial milestone payments and royalties. LATEST NEWS: We just announced a new collaboration w/ @VoyagerTx focused on developing potential treatments for Parkinson's disease.
Shares of Voyager Therapeutics Inc. ran up 14.2% in premarket trade Friday, after the gene therapy company and AbbVie Inc. announced a collaboration to develop antibodies to treat Parkinson's disease. AbbVie's stock was still inactive ahead of the open. Under terms of the collaboration, Voyager will receive $65 million upfront and up to $245 million in preclinical and phase 1 option payments, as well as up to an additional $728 million in potential milestone payments and royalties. Voyager is also eligible to earn up to a total of $500 million in commercial milestones. Voyager's stock has lost 10% over the past three months, while AbbVie shares have declined 8.6% and the S&P 500 has gained 4.7%.
The delivery of sufficient quantities of antibodies across the blood-brain barrier is one of the major limitations of current biologic therapies for neurodegenerative diseases that require frequent systemic injections with large amounts of antibodies. Voyager’s vectorized antibody platform and approach aims to circumvent this limitation by delivering, with a potential one-time intravenous administration, the genes that encode for the production of therapeutic antibodies utilizing Voyager’s blood-brain barrier penetrant adeno-associated virus (AAV) capsids.
- Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein - Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase ...
CAMBRIDGE, Mass., Feb. 19, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
CAMBRIDGE, Mass., Feb. 18, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
JERSEY CITY, N.J.-- -- Smart order routing technology connects to multiple exchanges and liquidity providers for access to more liquidity and better trade execution End-to-end solution enables trading with crypto wallet and custody solutions Advanced analytics, alerts, news feeds to research investments, monitor positions Instant funding and trading of 18 crypto assets with zero-commissions Voyager ...